UBS’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q2
Sell
-1,500
Closed -$20K 11441
2014
Q1
$20K Sell
1,500
-5,700
-79% -$89.2K ﹤0.01% 8127
2013
Q4
$116K Buy
7,200
+2,500
+53% +$39.8K ﹤0.01% 5906
2013
Q3
$78K Buy
4,700
+4,200
+840% +$62.1K ﹤0.01% 6316
2013
Q2
$5K Buy
+500
New +$5.25K ﹤0.01% 9359

Other funds holding OSIR

UBS's OSIR Position: Q3 2014 in Review

UBS increased its Osiris Therapeutics, Inc. Common Stock (OSIR) stake by 512% in Q3 2014, buying an estimated $117K and bringing the position to 9,799 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #5755.

UBS first reported a position in OSIR in Q2 2013 and has held it in 6 quarters since. The position peaked at $292K in Q3 2013. 67 funds tracked by Wall St. Rank hold OSIR as of Q3 2014.

  • UBS held 9,799 shares of Osiris Therapeutics, Inc. Common Stock worth $123K as of Q3 2014.
  • UBS bought 8,199 Osiris Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $117K.
  • Osiris Therapeutics, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5755 holding.
  • UBS first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 6 quarters since.
  • UBS's Osiris Therapeutics, Inc. Common Stock position peaked at $292K in Q3 2013.
  • 67 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.